SAGE - Sage Therapeutics drug benefits cognitive function in phase 2 trial in Parkinson's

Sage Therapeutics (NASDAQ:SAGE) said that data from a phase 2 trial showed SAGE-718 was associated with improvements on multiple tests of functioning and learning and memory in patients with mild cognitive impairment (MCI) due to Parkinson’s disease (PD) In the PARADIGM study (Part A), a range of tests were used to assess multiple domains of cognitive performance in 11 patients receiving SAGE-718 3 mg once daily. The company said SAGE-718 was linked with improved performance at Day 14, compared to baseline, on tests of executive functioning, and an emerging signal suggests improved performance on tests of learning and memory. In addition, sustained effects and improving trends were seen out to Day 28 for assessments completed at the follow-up visit. However, no appreciable effect was seen on measures of simple attention/psychomotor speed, in keeping with the profile of SAGE-718 based on data to date. The company noted that the data support

For further details see:

Sage Therapeutics drug benefits cognitive function in phase 2 trial in Parkinson’s